AR110498A1 - DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 - Google Patents
DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5Info
- Publication number
- AR110498A1 AR110498A1 ARP170103429A ARP170103429A AR110498A1 AR 110498 A1 AR110498 A1 AR 110498A1 AR P170103429 A ARP170103429 A AR P170103429A AR P170103429 A ARP170103429 A AR P170103429A AR 110498 A1 AR110498 A1 AR 110498A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- iii
- halo
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title 1
- 108091008681 GABAA receptors Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Composiciones que incluye los compuestos y uso de los compuestos en el tratamiento de la enfermedad de Alzheimer. Reivindicación 1: Compuestos de fórmula (1) en donde X se selecciona de entre i) N, y ii) CH; Y se selecciona de entre i) N, y ii) CR¹⁰; Z se selecciona de entre i) N, y ii) CR¹¹; R¹ se selecciona de entre i) alquilo C₁₋₆, ii) halo-alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) halo-alcoxi C₁₋₆, v) hidroxi-alquilo C₁₋₆, vi) cicloalquilo C₃₋₈, vii) halógeno, y viii) amino sustituido en el átomo de nitrógeno con uno o dos sustituyentes seleccionados independientemente de entre a) H, b) alquilo C₁₋₆, y c) cicloalquilo C₃₋₈; R² se selecciona de entre i) H, y ii) halógeno; R³ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) cicloalquilo C₃₋₈, iv) hidroxi-alquilo C₁₋₆, y v) halo-alquilo C₁₋₆; R⁴ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) cicloalquilo C₃₋₈, y v) halógeno; R⁵ es H; R⁶ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) cicloalquilo C₃₋₈ sustituido con R⁷, R⁸ y R⁹, iv) cicloalquil C₃₋₈-alquilo C₁₋₆ sustituido con R⁷, R⁸ y R⁹, v) alquilsulfonil C₁₋₆-alquilo C₁₋₆, vi) ciano-alquilo C₁₋₆, vii) hidroxi-alquilo C₁₋₆, viii) dihidroxi-alquilo C₁₋₆, ix) halo-alquilo C₁₋₆, x) heterocicloalquilo sustituido con R⁷, R⁸ y R⁹, y xi) heterocicloalquil-alquilo C₁₋₆ sustituido con R⁷, R⁸ y R⁹; R⁷, R⁸ y R⁹ se seleccionan independientemente de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) alcoxialquilo C₁₋₆, v) alcoxicarbonilo C₁₋₆, vi) ciano, vii) cicloalcoxi C₃₋₈, viii) cicloalquilo C₃₋₈, ix) halo-alcoxi C₁₋₆, x) halo-alquilo C₁₋₆, xi) halógeno, xii) hidroxi, xiii) hidroxi-alquilo C₁₋₆, y xiv) oxo; R¹⁰ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) cicloalquilo C₃₋₈, y v) halógeno; R¹¹ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) cicloalquilo C₃₋₈, y v) halógeno; o R⁵ y R¹⁰ forman juntos -(CH₂)ₙ-; o R⁵ y R¹¹ forman juntos -(CH₂)ₙ-; o R⁵ y R⁶ junto con el átomo de nitrógeno al que están unidos forman un heterocicloalquilo sustituido con R⁷, R⁸ y R⁹; n se selecciona de entre 1 y 2; o sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202889 | 2016-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110498A1 true AR110498A1 (es) | 2019-04-03 |
Family
ID=57530563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103429A AR110498A1 (es) | 2016-12-08 | 2017-12-07 | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11091471B2 (es) |
| EP (1) | EP3551627B1 (es) |
| JP (1) | JP7084405B2 (es) |
| KR (1) | KR102564643B1 (es) |
| CN (2) | CN109923113B (es) |
| AR (1) | AR110498A1 (es) |
| AU (1) | AU2017373734B2 (es) |
| BR (1) | BR112019006571A2 (es) |
| CA (1) | CA3040024A1 (es) |
| CL (1) | CL2019001458A1 (es) |
| CO (1) | CO2019002692A2 (es) |
| CR (1) | CR20190268A (es) |
| DK (1) | DK3551627T3 (es) |
| ES (1) | ES2910110T3 (es) |
| HR (1) | HRP20220468T1 (es) |
| HU (1) | HUE058355T2 (es) |
| IL (1) | IL267054B (es) |
| LT (1) | LT3551627T (es) |
| MA (1) | MA48594B1 (es) |
| MX (1) | MX2019006696A (es) |
| PE (1) | PE20191156A1 (es) |
| PH (1) | PH12019500664B1 (es) |
| PL (1) | PL3551627T3 (es) |
| PT (1) | PT3551627T (es) |
| RS (1) | RS63106B1 (es) |
| SI (1) | SI3551627T1 (es) |
| TW (1) | TWI642666B (es) |
| UA (1) | UA125524C2 (es) |
| WO (1) | WO2018104419A1 (es) |
| ZA (1) | ZA201902225B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018104419A1 (en) | 2016-12-08 | 2018-06-14 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| BR112020025355A2 (pt) | 2018-06-13 | 2021-03-09 | F. Hoffmann-La Roche Ag | Derivados de éter de isoxazolila como gaba a alfa5 pam |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| TW202202495A (zh) * | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物 |
| WO2021191837A1 (en) * | 2020-03-26 | 2021-09-30 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators |
| US20240425491A1 (en) | 2021-05-05 | 2024-12-26 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
| HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| IL316702A (en) | 2022-06-20 | 2024-12-01 | Hoffmann La Roche | Crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl)methoxy)-N-(tetrahydropyran-4-yl)pyridazine-3-carboxamide |
| WO2024088928A1 (en) | 2022-10-25 | 2024-05-02 | F. Hoffmann-La Roche Ag | Process for manufacturing alogabat |
| WO2024223450A1 (en) | 2023-04-24 | 2024-10-31 | F. Hoffmann-La Roche Ag | Tablet comprising 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl)methoxy)- n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide |
| CN119080754A (zh) * | 2023-06-05 | 2024-12-06 | 武汉人福创新药物研发中心有限公司 | 作为α5-GABAA受体调节剂的杂环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682301A1 (en) | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Xanthine compounds having a positive allosteric gabab receptor modulator effect |
| RS54355B1 (en) | 2007-12-04 | 2016-04-28 | F. Hoffmann-La Roche Ag. | Isoxazole-pyridine derivatives |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| EP2427456B1 (en) | 2009-05-05 | 2020-02-05 | F.Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| CN103189062B (zh) | 2010-11-05 | 2016-03-23 | 霍夫曼-拉罗奇有限公司 | 活性药物化合物用于治疗中枢神经系统病症的用途 |
| JP6012735B2 (ja) * | 2011-09-15 | 2016-10-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ジヒドロキノリン−２−オン誘導体 |
| KR20180037265A (ko) | 2015-08-17 | 2018-04-11 | 루핀 리미티드 | Parp 억제제로서의 헤테로아릴 유도체 |
| ES2963759T3 (es) | 2016-01-08 | 2024-04-01 | Arcus Biosciences Inc | Moduladores de la 5'-nucleotidasa, ecto y su uso |
| BR112018013761A2 (pt) | 2016-01-08 | 2018-12-11 | Celgene Corp | compostos antiproliferativos e suas composições farmacêuticas e usos |
| WO2018104419A1 (en) | 2016-12-08 | 2018-06-14 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as gaba a alpha5 pam |
-
2017
- 2017-12-07 WO PCT/EP2017/081768 patent/WO2018104419A1/en active Application Filing
- 2017-12-07 ES ES17816630T patent/ES2910110T3/es active Active
- 2017-12-07 AU AU2017373734A patent/AU2017373734B2/en active Active
- 2017-12-07 MA MA48594A patent/MA48594B1/fr unknown
- 2017-12-07 SI SI201731124T patent/SI3551627T1/sl unknown
- 2017-12-07 DK DK17816630.2T patent/DK3551627T3/da active
- 2017-12-07 CN CN201780069758.2A patent/CN109923113B/zh active Active
- 2017-12-07 AR ARP170103429A patent/AR110498A1/es unknown
- 2017-12-07 JP JP2019530755A patent/JP7084405B2/ja active Active
- 2017-12-07 UA UAA201907047A patent/UA125524C2/uk unknown
- 2017-12-07 HR HRP20220468TT patent/HRP20220468T1/hr unknown
- 2017-12-07 HU HUE17816630A patent/HUE058355T2/hu unknown
- 2017-12-07 MX MX2019006696A patent/MX2019006696A/es unknown
- 2017-12-07 CR CR20190268A patent/CR20190268A/es unknown
- 2017-12-07 LT LTEPPCT/EP2017/081768T patent/LT3551627T/lt unknown
- 2017-12-07 EP EP17816630.2A patent/EP3551627B1/en active Active
- 2017-12-07 PL PL17816630T patent/PL3551627T3/pl unknown
- 2017-12-07 CN CN202311216893.9A patent/CN117285525A/zh active Pending
- 2017-12-07 PT PT178166302T patent/PT3551627T/pt unknown
- 2017-12-07 CA CA3040024A patent/CA3040024A1/en active Pending
- 2017-12-07 BR BR112019006571A patent/BR112019006571A2/pt active Search and Examination
- 2017-12-07 RS RS20220321A patent/RS63106B1/sr unknown
- 2017-12-07 TW TW106142872A patent/TWI642666B/zh active
- 2017-12-07 PE PE2019001006A patent/PE20191156A1/es unknown
- 2017-12-07 KR KR1020197016011A patent/KR102564643B1/ko active IP Right Grant
- 2017-12-07 PH PH1/2019/500664A patent/PH12019500664B1/en unknown
-
2019
- 2019-03-26 CO CONC2019/0002692A patent/CO2019002692A2/es unknown
- 2019-04-09 ZA ZA2019/02225A patent/ZA201902225B/en unknown
- 2019-05-29 CL CL2019001458A patent/CL2019001458A1/es unknown
- 2019-06-03 IL IL267054A patent/IL267054B/en unknown
- 2019-06-05 US US16/432,584 patent/US11091471B2/en active Active
-
2021
- 2021-07-16 US US17/378,410 patent/US20220411415A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,606 patent/US20240279218A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR116913A1 (es) | Inhibidores de apol1 y sus métodos de uso | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR101489A1 (es) | Compuestos reguladores del crecimiento vegetal | |
| AR099690A1 (es) | Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| AR096827A1 (es) | Uso de piridoncarboxamidas seleccionadas o sus sales como ingredientes activos contra estrés abiótico en plantas |